Sagaal bilood ka dib markii lagu soo bandhigay Maraykanka, Eisai iyo Biogen's Alzheimer's dawada Leqembi waa la kulmid iska caabin weyn oo ku saabsan korsashadiisa baahsan, taas oo ay ugu wacan tahay shakiga ka dhex jira dhakhaatiirta qaar ee ku saabsan waxtarka daaweynta cudurkan maskaxda ee xumaaday.
In kasta oo ay tahay dawada ugu horreysa ee la caddeeyo inay hoos u dhigto horumarka Alzheimers, shaki ku qotoma bixiyeyaasha daryeelka caafimaadka ee ku saabsan qiimaha daaweynta xaaladda ayaa caddaynaya inay caqabad weyn tahay.
Khabiirada Alzheimers ayaa markii hore filayey caqabado la xiriira nidaamka dalabka Leqembi, kaas oo ay ku jiraan baaritaanno dheeraad ah oo lagu ogaanayo, faleebo laba bilood ah, iyo baaritaanno maskaxeed oo joogto ah si ay ula socdaan saameynaha daran ee suurtagalka ah. Runtii, shuruudahan ayaa gacan ka geystay gaabiska daawada tan iyo markii ay ansixisay Maamulka Cuntada iyo Dawooyinka ee Mareykanka, sida lagu caddeeyey wadahadal lala yeeshay 20 dhakhaatiirta neerfayaasha iyo takhaatiirta guud ee gobollada kala duwan ee Mareykanka.
Sida laga soo xigtay wakaaladda wararka ee Reuters, toddobo dhakhtar ayaa daaha ka qaaday inay ka labalabayaan inay qoraan Leqembi, iyagoo sabab uga dhigaya shakiga laga qabo waxtarka dawada, kharashkeeda, iyo khataraha la xidhiidha. Waxaa intaa dheer, koox ka kooban lix khabiir oo hormuud ka ah goobta ayaa tilmaamay in "nihilism-ka daaweynta" - aragtida ah in Alzheimer's uu yahay xaalad aan laga gudbi karin - uu saameyn weyn ku yeelanayo sidii la filayay si loo xaddido xamaasadda dhakhaatiirta daryeelka aasaasiga ah, dhakhaatiirta geriatrics, iyo dhakhaatiirta neerfaha. Shakigaani wuxuu saameeyaa rabitaankooda ah inay u gudbiyaan bukaanada takhasuska xusuusta si ay ugu daaweeyaan Leqembi.
Khubarada qaar ayaa sheegaya in diidmada dhakhaatiirta qaarkood ay ka iman karto muddada dheer ee shakiga ee mugdi geliyay waxtarka bartilmaameedka borotiinka Alzheimers beta amyloid si loo yareeyo horumarka cudurka. Kahor natiijooyinka dhiirigelinta leh ee tijaabada Leqembi, qaar badan oo ka mid ah goobaha caafimaadka ayaa u tixgeliyey jihada cilmi-baarista mid aan midho lahayn.
Walaaca waxaa soo jeediyay khubarada kale ee caafimaadka ee ku saabsan dhibaatooyinka soo raaca ee Leqembi, sida bararka maskaxda iyo dhiig-baxa, marka lagu daro kharashyada ku lug leh qiimaha sanadlaha ah ee $26,500, MRI-yada soo noqnoqda, iyo faleebooyinka laba-biloodlaha ah.
Leqembi waxay ahayd daawadii ugu horreysay ee bartilmaameedka amyloid-ka si ay u hesho oggolaansho buuxda oo FDA ah ka dib markii ay muujisay hoos u dhac 27% ah ee hoos u dhaca garashada ee bukaannada hore ee Alzheimers inta lagu jiro tijaabooyinka caafimaad. In kasta oo hadafkii hore ee ahaa in lagu daweeyo 10,000 Maraykan ah dhamaadka March, kaliya dhawr kun ayaa bilaabay daawaynta dhamaadka Janaayo, sida uu sheegay Eisai, oo afhayeenadiisu ay diiday inay bixiso tirooyin la cusboonaysiiyay.
Qaadashada dawooyinka cusub, xitaa kuwa aan u baahnayn isbeddello la taaban karo oo ku saabsan dhaqanka caafimaadka, ayaa si caan ah u gaabis ah. Cilmi baaris ayaa muujisay in ay qaadan karto celcelis ahaan 17 sano in cilmi-baaris caafimaad ay noqoto mid joogto ah. Alzheimer's wuxuu saameeyaa in ka badan 6 milyan oo Maraykan ah, in ka yar kala badh dhakhaatiirta neerfayaasha ee Maraykanka ayaa kula talinayaa Leqembi bukaankooda, sida ku cad sahan nolosha ah ee Janaayo sayniska cilmi-baare suuqa Spherix Global Insights.
Written by Alius Noreika
